All In Biotech

NDA 008845 · Hospira

Quelicin Preservative Free

Succinylcholine Chloride · Injection

Last checked: Nov 20, 2026Latest source record: Dec 1, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1953

May 1, 1953

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

13 Phase 3, 4 recruiting

FAERS reports

2,125

1,784 serious, 245 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: VENTRICULAR DYSRHYTHMIAS, CARDIAC ARREST, AND DEATH FROM HYPERKALEMIC RHABDOMYOLYSIS IN PEDIATRIC PATIENTS • Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy [see Warnings and Precautions (5.1) ] . • When a healthy appearing pediatric patient develops cardiac arrest within minutes after administration of QUELICIN, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. In the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently [see Warnings and Precautions (5.1) ] . • Reserve the...

What it is approved for

From the label in effect Aug 18, 2026.

QUELICIN is indicated in adults and pediatric patients: • as an adjunct to general anesthesia • to facilitate tracheal intubation • to provide skeletal muscle relaxation during surgery or mechanical ventilation. QUELICIN is a depolarizing neuromuscular blocker indicated in adults and pediatric patients: • as an adjunct to general anesthesia ( 1 ) • to facilitate tracheal intubation ( 1 ) • to provide skeletal muscle relaxation during surgery or mechanical ventilation. ( 1 )

Mechanism: Succinylcholine is a depolarizing neuromuscular blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the receptor site. Onset of flaccid paralysis is rapid (less than one minute after intravenous administration), and with single administration lasts approximately 4 to 6 minutes. The paralysis following administration of succinylcholine is progressive,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 1, 1953 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • QUELICIN PRESERVATIVE FREE · SUCCINYLCHOLINE CHLORIDE 20MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • QUELICIN · SUCCINYLCHOLINE CHLORIDE 20MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • QUELICIN PRESERVATIVE FREE · SUCCINYLCHOLINE CHLORIDE 100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • QUELICIN PRESERVATIVE FREE · SUCCINYLCHOLINE CHLORIDE 50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Succinylcholine Chloride" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective288
  • hypotension178
  • cardiac arrest165
  • anaphylactic shock146
  • drug interaction127
  • anaphylactic reaction113
  • renal failure101
  • renal impairment99
  • hyperthermia malignant98
  • pain98
  • maternal exposure during pregnancy91
  • anxiety88

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200494
200532
200641
200755
200846
200957
201074
2011196
201294
201333
201430
201544
201684
2017115
201897
2019154
2020154
2021127
2022125
2023122
2024105
2025159
202687

Recalls

3 FDA enforcement reports for this application.

  • Jun 15, 2017 · Class II · Terminated

    Lack of Sterility Assurance

  • Mar 15, 2016 · Class III · Ongoing

    Labeling: Incorrect or Missing Lot and/or Exp Date: Potential for the lot number and/or expiration date to be faded or missing from the primary label on the glass vial.

  • Feb 26, 2013 · Class II · Terminated

    Lack of Assurance of Sterility: Loose crimp applied to the fliptop vial.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Pfizer · Also marketed as Quelicin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.